Lipella Pharmaceuticals Inc.

Lipella is a privately-held biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, also called radiation cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatment of oral lichen planus. Our lead product, LP-10 for hemorrhagic cystitis is currently in a phase-2, multi-center clinical trial, and our pipeline asset, LP-310, recently received FDA Type-B Pre-IND guidance. We maintain a pipeline of additional product candidates consistent with our strategy of developing proprietary 505(b)(2) assets that address highly-morbid indications where no adequate treatment(s) exists.